Press Release
January 4, 2019

C4 Therapeutics and Roche Expand Strategic Collaboration to Discover and Develop Degrader-Based Medicines

The Life Sciences team advised C4 Therapeutics (C4T) on its expanded partnership with Roche to research and develop new cancer treatments based on C4T’s targeted protein degradation technology.

Under the terms of the agreement, C4T will lead efforts from discovery through defined preclinical or early clinical milestones, depending on the program. Upon C4T reaching these milestone events, Roche will have exclusive options for worldwide rights to continue development and commercialize drugs from these programs. In addition, C4T will have the option to co-develop and co-promote in the U.S. on selected programs. C4T will receive a significant upfront payment and near-term preclinical milestones. Upon success C4T may also receive royalties and potential clinical, regulatory, and commercial milestone payments totaling over $900 million.

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell.

The Goodwin team included partner Lawrence Wittenberg and associate Emily Beman.

For additional details on the collaboration, please read the press release.